Hengrui (恒瑞医药) A/H Listing: A Worthy Comparison with Hansoh Pharma
China's Jiangsu Hengrui Medicine plans to raise $2bn in H-share listing. We did a worthy comparison between it and Hansoh Pharma.
643 Views
PegBio 派格生物 IPO: A (Supposedly) Straightforward GLP-1 Challenger Story
PegBio plans to raise $100m in Hong Kong IPO, with focus on core product PB-117 as a GLP-1 challenger, but concerns arise upon closer examination...
423 Views
APAC Healthcare Weekly (Jan 19)- Samsung Biologics, Daiichi Sankyo, Eisai, Sun Pharma, Biocon
APAC healthcare companies got approvals for new products as well as clinical trials. The companies continued with acquisitions and collaborations...
541 Views
EQD | Hong Kong Single Stock Options Weekly January 06 – 10
Investors remain calm despite majority of optionable stocks declining, with preference for Calls over Puts; Tencent dominates option trading...
245 Views
Wuxi XDC Placement - A Repeat of Biologics Placement Saga, Last Deal Did Well
WuXi AppTec (2359 HK) aims to raise around US$150m via selling around 3% stake in WuXi XDC Cayman (2268 HK). It has sold earlier in Nov 24 as well.
720 Views